Cardiopulmonary complications of ergot-derivative dopamine agonists.
Rack
Michael J
MJ
Baran
Alp Sinan
AS
Richert
Allen C
AC
Roffwarg
Howard P
HP
D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001971:Bromocriptine / Q000009:adverse effects; D000077465:Cabergoline; D018491:Dopamine Agonists / Q000009:adverse effects* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004873:Ergolines / Q000009:adverse effects* / Q000627:therapeutic use; D006349:Heart Valve Diseases / Q000139:chemically induced* / Q000453:epidemiology; D006801:Humans; D006966:Hyperprolactinemia / Q000139:chemically induced* / Q000188:drug therapy*; D010479:Pergolide / Q000009:adverse effects; D011658:Pulmonary Fibrosis / Q000139:chemically induced* / Q000453:epidemiology; D018967:Risperidone / Q000009:adverse effects* / Q000627:therapeutic use
D014150:Antipsychotic Agents; D018491:Dopamine Agonists; D004873:Ergolines; D010479:Pergolide; D001971:Bromocriptine; D018967:Risperidone; D000077465:Cabergoline